Free tool
Healthcare stocks
We cover 36 companies in the Healthcare sector. The median market value in the group is $4.55B. Across the group, the median move over the past trading day is −0.30%. 100% of the 36 with a 200-day average trade above it. Price change over the past year runs from +18.5% to +269.5% across the middle 80 percent of the group, with a median of +64.0%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
Table
36 of 2,203 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| ARGX | argenx SE | $65.51B | Large cap | +47.90% |
| BDX | Becton, Dickinson and Company | $51.81B | Large cap | +25.97% |
| NTRA | Natera, Inc. | $48.53B | Large cap | +107.59% |
| IQV | IQVIA Holdings Inc. | $43.04B | Large cap | +38.51% |
| ILMN | Illumina, Inc. | $33.95B | Large cap | +125.88% |
| LH | Labcorp Holdings Inc. | $27.39B | Large cap | +21.14% |
| DGX | Quest Diagnostics Incorporated | $26.99B | Large cap | +38.12% |
| CRL | Charles River Laboratories International, Inc. | $14.09B | Large cap | +81.27% |
| HALO | Halozyme Therapeutics, Inc. | $12.41B | Large cap | +46.30% |
| BIO | Bio-Rad Laboratories, Inc. | $10.40B | Large cap | +32.71% |
| RGEN | Repligen Corporation | $10.25B | Large cap | +51.67% |
| APGE | Apogee Therapeutics, Inc. | $10.21B | Large cap | +257.11% |
| BIO-B | Bio-Rad Laboratories, Inc. | $9.77B | Mid cap | +47.78% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +179.08% |
| TXG | 10x Genomics, Inc. | $8.37B | Mid cap | +358.35% |
| CAI | Caris Life Sciences, Inc. | $7.58B | Mid cap | −29.83% |
| CNTA | Centessa Pharmaceuticals plc | $6.27B | Mid cap | +143.24% |
| HAE | Haemonetics Corporation | $4.85B | Mid cap | +93.71% |
| HTFL | Heartflow, Inc. | $4.26B | Mid cap | +40.79% |
| ITGR | Integer Holdings Corporation | $4.25B | Mid cap | +15.84% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.13B | Mid cap | +292.38% |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | +66.32% |
| ABCL | AbCellera Biologics Inc. | $3.97B | Mid cap | +181.38% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +55.97% |
| OGN | Organon & Co. | $3.62B | Mid cap | +50.67% |
| PLSE | Pulse Biosciences, Inc. | $3.43B | Mid cap | +203.47% |
| MRVI | Maravai LifeSciences Holdings, Inc. | $3.30B | Mid cap | +281.97% |
| AVAH | Aveanna Healthcare Holdings Inc. | $2.97B | Mid cap | +73.50% |
| ZLAB | Zai Lab Limited | $2.92B | Mid cap | −20.06% |
| ATAI | AtaiBeckley Inc. | $2.74B | Mid cap | +61.71% |
| CDNA | CareDx, Inc. | $2.64B | Mid cap | +283.45% |
| RAPP | Rapport Therapeutics, Inc. | $2.52B | Mid cap | +250.70% |
| ATRC | AtriCure, Inc. | $2.45B | Mid cap | +29.14% |
| XNCR | Xencor, Inc. Common Stock | $2.11B | Mid cap | +254.61% |
| ZYME | Zymeworks Inc. | $2.10B | Mid cap | +96.28% |
| PRGO | Perrigo Company plc | $2.05B | Mid cap | −36.05% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.